TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
Eckardt J, Schroeder C, Martus P, Armeanu-Ebinger S, Kelemen O, Gschwind A, Bonzheim I, Eigentler T, Amaral T, Ossowski S, Rieß O, Flatz L, Garbe C, Forschner A.
Eckardt J, et al. Among authors: amaral t.
J Cancer Res Clin Oncol. 2023 Feb;149(2):833-840. doi: 10.1007/s00432-022-03939-w. Epub 2022 Feb 22.
J Cancer Res Clin Oncol. 2023.
PMID: 35192052
Free PMC article.